SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-074238
Filing Date
2023-09-06
Accepted
2023-09-06 12:01:30
Documents
3
Period of Report
2023-09-06

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea184754-6k_scinaiimmu.htm 6-K 10553
2 PRESS RELEASE DATED SEPTEMBER 6, 2023, "BIONDVAX PHARMACEUTICALS LTD. REBRANDS A ea184754ex99-1_scinai.htm EX-99.1 17529
3 GRAPHIC ex99-1_001.jpg GRAPHIC 20863
  Complete submission text file 0001213900-23-074238.txt   58161
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
Scinai Immunotherapeutics Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 231238415
SIC: 2836 Biological Products, (No Diagnostic Substances)